FDA advisers vote on Grail Galleri multicancer blood test approval

The FDA's advisory panel is voting on whether to recommend approval of Grail's Galleri blood test, which detects up to 50 cancer types. Approval could lead to Medicare reimbursement enabled by recent legislation and an FDA-CMS RAPID pathway, significantly reducing market access time.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure, and 9 sources have reported it between 23 Sep 2026 and 24 Sep 2026.